Richard Casaburi
Pulmonary Disease · Torrance, CANPI 1639149289
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. GSK accounts for 60.3% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2019 at $143,184 and has fallen 99.9% since, to $163 in 2025. Among pulmonary disease clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 183 payments — averaging $1137.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$126K
- Boehringer Ingelheim International GmbH$21K
- Genentech, Inc.$19K
- Regeneron$9K
- Inogen, Inc.$8K
- Viiv Healthcare Company$7K
- plus $18K from 8 others
Across 3 payments — averaging $6229.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$17K
- F. Hoffmann-la Roche AG$2K
What the payments were for
- Consulting fees$65,86832%
- Speaking & faculty fees$115,46455%
- Travel & lodging$23,05611%
- Food & beverage$3,6942%
- Education$420%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 138 | $125,559 |
| Boehringer Ingelheim International GmbH | 7 | $21,324 |
| Genentech, Inc. | 6 | $19,181 |
| Regeneron | 2 | $9,113 |
| Inogen, Inc. | 4 | $8,247 |
| Viiv Healthcare Company | 3 | $6,556 |
| Boehringer Ingelheim | 4 | $6,123 |
| AstraZeneca | 11 | $5,706 |
| Abbott | 3 | $5,600 |
| Boehringer Ingelheim Taiwan Ltd. | 1 | $520 |
| Verona Pharma, Inc. | 1 | $107 |
| Cleerly, Inc. | 1 | $56 |
| Pfizer | 1 | $19 |
| AbbVie | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$82,796
- XOLAIR$15,261
- ANORO$13,838
- DUPIXENT$9,113
- INOGEN$6,768
- FreeStyle Libre Pro$5,600
- FASENRA$4,890
- STIOLTO$4,726
- Avastin$3,920
- Herceptin$3,920
- Lucentis$3,920
- Rituxan$3,920
- Tamiflu$3,920
- STIOLTO RESPIMAT$3,898
- NUCALA$3,250
- SPIRIVA$2,600
- SPIRIVA RESPIMAT$1,500
- InogenOne$1,478
- ANORO ELLIPTA$1,200
- SYMBICORT$600
How this compares
$208,124 in reported general payments places this provider in the 95th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in Torrance
- Catherine ObergTorrance$457K
- Samuel LouieSacramento$2.8M
- Shyamsunder SubramanianTracy$1.5M
- Toby MaherLos Angeles$1.3M
- Rajkumar DasguptaPasadena$930K
- Hoang leFountain Valley$814K
- Kevin FussellEncinitas$788K
- Revati ShreeniwasStanford$726K
- David PhamWestminster$571K
- Vijay BalasubramanianFresno$529K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.